Il nostro contributo

L’impatto scientifico misura l’influenza e la rilevanza delle scoperte e delle pubblicazioni di un istituto di ricerca. Per IFOM, l’impatto scientifico non si limita solo alla quantità di pubblicazioni, ma si estende alla qualità delle riviste su cui vengono pubblicati i nostri studi, alla visibilità dei nostri risultati e alla capacità di trasformare queste scoperte in avanzamenti concreti nella lotta contro il cancro.

Kajiho H, Kajiho Y, Frittoli E, Confalonieri S, Bertalot G, Viale G, Di Fiore PP, Oldani A, Garre M, Beznoussenko GV, Palamidessi A, Vecchi M, Chavrier P, Perez F, Scita G

RAB2A controls MT1-MMP endocytic and E-cadherin polarized Golgi trafficking to promote invasive breast cancer programs.

EMBO Rep 2016; 1061-80. doi: 10.15252/embr.201642032

Pozzi C, Cuomo A, Spadoni I, Magni E, Silvola A, Conte A, Sigismund S, Ravenda PS, Bonaldi T, Zampino MG, Cancelliere C, Di Fiore PP, Bardelli A, Penna G, Rescigno M

The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.

Nat Med 2016; 624-31. doi: 10.1038/nm.4078

Petrakis TG, Komseli ES, Papaioannou M, Vougas K, Polyzos A, Myrianthopoulos V, Mikros E, Trougakos IP, Thanos D, Branzei D, Townsend P, Gorgoulis VG

Exploring and exploiting the systemic effects of deregulated replication licensing.

Semin Cancer Biol 2016; 3-15. doi: 10.1016/j.semcancer.2015.12.002

Pusceddu S, Buzzoni R, Vernieri C, Concas L, Marceglia S, Giacomelli L, Milione M, Leuzzi L, Femia D, Formisano B, Mazzaferro V, de Braud F

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.

Future Oncol 2016; 1251-60. doi: 10.2217/fon-2015-0077

Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Cell 2016; 317-30. doi: 10.1016/j.cell.2016.02.059

Wollscheid HP, Biancospino M, He F, Magistrati E, Molteni E, Lupia M, Soffientini P, Rottner K, Cavallaro U, Pozzoli U, Mapelli M, Walters KJ, Polo S

Diverse functions of myosin VI elucidated by an isoform-specific α-helix domain.

Nat Struct Mol Biol 2016; 300-308. doi: 10.1038/nsmb.3187

He F, Wollscheid HP, Nowicka U, Biancospino M, Valentini E, Ehlinger A, Acconcia F, Magistrati E, Polo S, Walters KJ

Myosin VI Contains a Compact Structural Motif that Binds to Ubiquitin Chains.

Cell Rep 2016; 2683-94. doi: 10.1016/j.celrep.2016.01.079

Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

Sci Transl Med 2016; 324ra14. doi: 10.1126/scitranslmed.aad5640

Savio MG, Wollscheid N, Cavallaro E, Algisi V, Di Fiore PP, Sigismund S, Maspero E, Polo S

USP9X Controls EGFR Fate by Deubiquitinating the Endocytic Adaptor Eps15.

Curr Biol 2016; 173-183. doi: 10.1016/j.cub.2015.11.050

Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Bianchi AS, Li G, Siena S, Bardelli A

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

Cancer Discov 2016; 36-44. doi: 10.1158/2159-8290.CD-15-0940

Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.

J Natl Cancer Inst 2016; . doi: 10.1093/jnci/djv306

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

PLoS One 2016; e0149099. doi: 10.1371/journal.pone.0149099

Vernieri C, Femia D, Pusceddu S, Capella C, Rosai J, Calareso G, Concas L, Prinzi N, Lo Russo G, de Braud F, Buzzoni R

Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up.

Case Rep Oncol 2016; 432-439. doi: 10.1159/000447771

Awasthi P, Foiani M, Kumar A

ATM and ATR signaling at a glance.

J Cell Sci 2015; 4255-62. doi: 10.1242/jcs.169730

Mihailovich M, Bremang M, Spadotto V, Musiani D, Vitale E, Varano G, Zambelli F, Mancuso FM, Cairns DA, Pavesi G, Casola S, Bonaldi T

miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth.

Nat Commun 2015; 8725. doi: 10.1038/ncomms9725

Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

Cell Rep 2015; 1978-85. doi: 10.1016/j.celrep.2015.08.037

Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, Lin KH, Truini M, Trusolino L, Bertotti A, Di Nicolantonio F, Nowak MA, Zhang L, Wood KC, Bardelli A

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.

Nat Commun 2015; 8305. doi: 10.1038/ncomms9305

Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Rudà R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

Ann Oncol 2015; 1994-1999. doi: 10.1093/annonc/mdv272

Capuani F, Conte A, Argenzio E, Marchetti L, Priami C, Polo S, Di Fiore PP, Sigismund S, Ciliberto A

Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells.

Nat Commun 2015; 7999. doi: 10.1038/ncomms8999

Manfrini N, Clerici M, Wery M, Colombo CV, Descrimes M, Morillon A, d'Adda di Fagagna F, Longhese MP

Resection is responsible for loss of transcription around a double-strand break in Saccharomyces cerevisiae.

Elife 2015; . doi: 10.7554/eLife.08942

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Nat Med 2015; 795-801. doi: 10.1038/nm.3870

Xue X, Choi K, Bonner JN, Szakal B, Chen YH, Papusha A, Saro D, Niu H, Ira G, Branzei D, Sung P, Zhao X

Selective modulation of the functions of a conserved DNA motor by a histone fold complex.

Genes Dev 2015; 1000-5. doi: 10.1101/gad.259143.115

Meena JK, Cerutti A, Beichler C, Morita Y, Bruhn C, Kumar M, Kraus JM, Speicher MR, Wang ZQ, Kestler HA, d'Adda di Fagagna F, Günes C, Rudolph KL

Telomerase abrogates aneuploidy-induced telomere replication stress, senescence and cell depletion.

EMBO J 2015; 1371-84. doi: 10.15252/embj.201490070

Conti A, Majorini MT, Elliott R, Ashworth A, Lord CJ, Cancelliere C, Bardelli A, Seneci P, Walczak H, Delia D, Lecis D

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.

Oncotarget 2015; 10994-1008. doi: 10.18632/oncotarget.3552

Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Clin Cancer Res 2015; 2157-66. doi: 10.1158/1078-0432.CCR-14-2821

Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Nat Commun 2015; 7002. doi: 10.1038/ncomms8002

%PLACEHOLDER%